- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02624661
Glycerol Block of the Trigeminal Ganglion in Trigeminal Neuralgia Using a New Neuronavigation-based Surgical Technique
March 26, 2019 updated by: Norwegian University of Science and Technology
Trigeminal neuralgia is one of the strongest pains known to humans.
Some patients do not have enough effect with the available pharmaceutical treatments and are offered a type of surgery, which involves the injection of glycerol in a nerve structure called trigeminal ganglion.
The researchers will do a pilot study on 10 patients with a new surgical technique using neuronavigation.
The researchers believe that this new neuronavigation-based system can improve the precision of the technique and reduce the risk for complications.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Trondheim, Norway
- Department of Neuroscience, Norwegian University of Science and Technology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Informed and written consent
- Trigeminal neuralgia defined in International Classification of Headache Disorders (ICHD)-3 criteria
- Unsatisfactory effect of pharmacological treatment
Exclusion Criteria:
- Microvascular decompression is seen as a better alternative
- Heart or lung disease
- Any kind of systematic or local disease or illness that may significantly increase the risk of complications for the procedure related to injection
- Psychiatric illness that hinders participation in the study
- Known pregnancy or breast feeding
- Inadequate use of contraceptives
- Overuse or abuse of opioids
- Abuse of medications, narcotics or alcohol
- Anomalies which hinder or impede the used method of injection
- Allergy or any other hypersensitivity reactions against marcain, lidocaine, xylocain or adrenalin
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Glycerol injection
The patients will be injected with glycerol using a new neuronavigation-based technique in the trigeminal ganglion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events
Time Frame: For the follow-up period of 12 weeks
|
Number of adverse events and number of participants with adverse events after glycerol injection in the trigeminal ganglion and severity of adverse events by the method used.
Registration of any adverse events categorized by probable relationship to drug or the procedure.
Data obtained from the headache diaries as well as open questions during consultations.
|
For the follow-up period of 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of attacks with trigeminal neuralgia
Time Frame: 12 weeks
|
12 weeks
|
|
Intensity of the trigeminal neuralgia attacks assessed by Visual analogue scale
Time Frame: 12 weeks
|
expressed as score on Visual analogue scale (VAS) for pain
|
12 weeks
|
Intensity of the trigeminal neuralgia attacks assessed by questionnaire
Time Frame: 12 weeks
|
expressed by means of patient global impression of change questionnaire (PGIC)
|
12 weeks
|
Number of doses of common analgesics
Time Frame: 12 weeks
|
week 1-4, week 5-8, week 9-12
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Erling A Tronvik, PhD, MD, Norwegian University of Science and Technology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2016
Primary Completion (Actual)
January 1, 2019
Study Completion (Actual)
January 1, 2019
Study Registration Dates
First Submitted
November 26, 2015
First Submitted That Met QC Criteria
December 4, 2015
First Posted (Estimate)
December 8, 2015
Study Record Updates
Last Update Posted (Actual)
March 27, 2019
Last Update Submitted That Met QC Criteria
March 26, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Pain
- Neurologic Manifestations
- Cysts
- Connective Tissue Diseases
- Neuromuscular Diseases
- Stomatognathic Diseases
- Mouth Diseases
- Peripheral Nervous System Diseases
- Mucinoses
- Cranial Nerve Diseases
- Facial Nerve Diseases
- Trigeminal Nerve Diseases
- Facial Neuralgia
- Neuralgia
- Headache
- Ganglion Cysts
- Headache Disorders
- Trigeminal Neuralgia
- Physiological Effects of Drugs
- Protective Agents
- Cryoprotective Agents
- Glycerol
Other Study ID Numbers
- 2015/1192
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Headache Disorders
-
Canadian Memorial Chiropractic CollegeDr. Zaxx Co.UnknownMigraine Headache | Cervicogenic Headache | Tension-type HeadacheCanada
-
University GhentRecruitingTension-Type Headache | Cervicogenic Headache | Myofascial HeadacheBelgium
-
Real Centro Universitario Maria CristinaRecruiting
-
Brooke Army Medical CenterThe University of Queensland; The Defense and Veterans Brain Injury CenterRecruitingHeadache, Migraine | Persistent Post Traumatic Headache | Cervicogenic HeadacheUnited States
-
University Hospital, GhentRecruitingMigraine Disorders | Headache Disorders | Tension-Type Headache | Cluster Headache | TACS | Secondary Headache DisorderBelgium
-
Wei DaiInternational Headache SocietyRecruitingMigraine Disorders | Medication-overuse HeadacheChina
-
VR1 CorporationTerminatedPrimary Headache DisordersUnited States
-
Bnai Zion Medical CenterUnknownChildren, Only | Headache, Migraine | Headache, TensionIsrael
-
Hospital of South West JutlandCompletedMedication-overuse Headache | Secondary Headache Disorders
-
University of British ColumbiaCompletedMigraine in Children | Posttraumatic HeadacheCanada
Clinical Trials on Glycerol
-
Francisco Javier Martínez NogueraCompletedAntioxidative Stress | Lactate Blood Increase | Performance Enhancing Product Use | Change, Body Weight | Change, Body Temperature | Thermal Sensation DisordersSpain
-
University of PittsburghHorizon Pharma Ireland, Ltd., Dublin IrelandCompletedMedium-chain Acyl-CoA Dehydrogenase (MCAD) DeficiencyUnited States
-
Ultragenyx Pharmaceutical IncCompletedGlucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)United States, Spain, Australia, France, Israel, Italy, United Kingdom
-
Orion Corporation, Orion PharmaCompleted
-
Institut National de la Santé Et de la Recherche...Completed
-
Robert Squires, Jr.No longer available
-
Laboratoires CARILENECompleted
-
University of Texas Southwestern Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...TerminatedHepatic Insufficiency | HypoalbuminemiaUnited States
-
Kamuzu University of Health SciencesCompleted
-
University of AarhusRecruitingLow Anterior Resection Syndrome | Rectal CancerDenmark